1476PD - Tumour necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma (STS)

Date 11 September 2017
Event ESMO 2017 Congress
Session Sarcoma
Topics Anti-Cancer Agents & Biologic Therapy
Cancer in Adolescents
Soft Tissue Sarcomas
Sarcoma
Presenter Jeremy Lewin
Citation Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387
Authors J. Lewin, S. Salah, E. Amir, A.R.A. Razak
  • Department Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, M5G2M9 - Toronto/CA

Abstract

Background

Tumour necrosis following chemotherapy is prognostic in bone sarcoma, but remains undefined in STS.

Methods

We searched MEDLINE, MEDLINE in progress, EMBASE and Cochrane to identify studies that investigated neoadjuvant therapy in STS. Eligible studies were required to have data on survival outcomes based on tumor necrosis in the resected specimen, or provided individual patient data. Hazard ratios (HR) for relapse free (RFS) and overall survival (OS) as well as odds ratios (OR) for recurrence at 3 years and for death at 5 years were pooled in a random effect meta-analysis. Association between patient characteristics and attainment of ≥ 90% necrosis were explored with logistic regression.

Results

21 studies comprising 1644 patients were included in this analysis. Location of the tumor included the extremities in the majority (n = 1459; 89%). Induction regimens included chemotherapy/radiation (n = 813; 49%), chemotherapy alone (n = 418; 25%), chemotherapy/caffeine (n = 81; 5%), radiotherapy alone (n = 78; 5%), isolated limb perfusion (ILP) with (n = 28; 2%) or without radiation (n = 208; 13%), and targeted therapy/radiotherapy (n = 18; 1%). Utilizing a cut-off of 90%, patients with ≥ 90% tumour necrosis had significantly reduced risk of recurrence at 3 years (OR0.30; 95% CI: 0.20-0.44; p 

Conclusions

Tumour necrosis ≥ 90% following neoadjuvant therapy is associated with reduced recurrence risk and improved overall survival in patients with STS.

Clinical trial identification

Legal entity responsible for the study

Princess Margaret Cancer Centre

Funding

None

Disclosure

All authors have declared no conflicts of interest.